Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Calvo

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Cell Reports|January 11, 2018
The RNA Polymerase II Factor RPAP1 Is Critical for Mediator-Driven Transcription and Cell IdentityCian J Lynch, Raquel Bernad, Isabel Calvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathyMaría Apellániz-Ruiz, Mi-Young Lee, Lara Sánchez-Barroso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
The Oncologist|November 25, 2018
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral NeuropathyLara Sánchez-Barroso, Maria Apellaniz-Ruiz, Gerardo Gutiérrez-Gutiérrez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy UpdateSibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2016
Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral NeuropathyMaría Apellániz-Ruiz, Héctor Tejero, Lucía Inglada-Pérez, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|June 12, 2021
Nutrition competencies for undergraduate medical education: Results of an international interdisciplinary consensusDiana Cardenas, Gustavo Díaz, Vanessa Fuchs-Tarlovsky, et al.
Journal of Feline Medicine and Surgery|September 21, 2023
Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)Samantha S Taylor, Sally Coggins, Emi N Barker, et al.
Nature Medicine|June 4, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trialMaría Gion, Isabel Blancas, Patricia Cortez-Castedo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2025
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 studyManuel Ruiz Borrego, David Páez López-Bravo, Mireia Margelí Vila, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Cell Reports|January 11, 2018
The RNA Polymerase II Factor RPAP1 Is Critical for Mediator-Driven Transcription and Cell IdentityCian J Lynch, Raquel Bernad, Isabel Calvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathyMaría Apellániz-Ruiz, Mi-Young Lee, Lara Sánchez-Barroso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
The Oncologist|November 25, 2018
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral NeuropathyLara Sánchez-Barroso, Maria Apellaniz-Ruiz, Gerardo Gutiérrez-Gutiérrez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy UpdateSibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2016
Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral NeuropathyMaría Apellániz-Ruiz, Héctor Tejero, Lucía Inglada-Pérez, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|June 12, 2021
Nutrition competencies for undergraduate medical education: Results of an international interdisciplinary consensusDiana Cardenas, Gustavo Díaz, Vanessa Fuchs-Tarlovsky, et al.
Journal of Feline Medicine and Surgery|September 21, 2023
Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)Samantha S Taylor, Sally Coggins, Emi N Barker, et al.
Nature Medicine|June 4, 2025
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trialMaría Gion, Isabel Blancas, Patricia Cortez-Castedo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2025
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 studyManuel Ruiz Borrego, David Páez López-Bravo, Mireia Margelí Vila, et al.
Pageof 11